ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression
Molecular Therapy · 2025-08 · 33 (8) · 3559-3575
DOI: 10.1016/j.ymthe.2025.04.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025-08. Verfasst von Jasmin Röder und 12 weiteren Autor:innen. Beteiligte Einrichtung: Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany; Frankfurt Cancer Institute, Goethe University, 605…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Organoids, Killer Cells, Natural, Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds der Chemischen Industrie, Bundesministerium für Gesundheit.
Abstract (Originalsprache)
Chimeric antigen receptor-engineered NK cells hold promise for adoptive cancer immunotherapy. In one such approach, the ErbB2 (HER2)-specific CAR-NK cell line NK-92/5.28.z is under investigation as an off-the-shelf therapy in a phase I trial in glioblastoma patients. To evaluate activity of NK-92/5.28.z cells against ErbB2-positive breast cancer, here we developed an organoid model derived from CKP mice that allows conditional activation of oncogenic driver mutations. Expression of ErbB2 and Cre recombinase in CKP mammary epithelial cells induced malignant transformation, with the resulting EC-CKP cells characterized by neoplastic morphology, loss of p53, and constitutive activation of the MAP kinase pathway. NK-92/5.28.z cells demonstrated potent CAR-mediated cytotoxicity against EC-CKP organoids, with tumor cell lysis dependent on exposure time and organoid size. In vivo passaging of EC-CKP organoids revealed cellular plasticity and induced an EMT phenotype associated with increased resistance to standard therapies. Importantly, NK-92/5.28.z cells retained high and specific cytotoxicity against these breast cancer cells in vitro and in an aggressive organoid-based in vivo mouse model that reflects advanced-stage disease. Our data highlight the therapeutic potential of NK-92/5.28.z cells against ErbB2-positive breast cancer, supporting their further development toward clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany; Frankfurt Cancer Institute, Goethe University, 60596 Frankfurt, Germany.
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany.
- Institute of Translational Immunology and Research Centre for Immunotherapy, Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.
- Frankfurt Cancer Institute, Goethe University, 60596 Frankfurt, Germany; Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt and Red Cross Blood Donation Service Baden-Württemberg-Hesse…
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany; Frankfurt Cancer Institute, Goethe University, 60596 Frankfurt, Germany; German Cancer Consortium (DKTK), partner site F…
Förderung
- Fonds der Chemischen Industrie
- Bundesministerium für Gesundheit
Zitieren
APA
Röder, J., Alekseeva, T., Kiefer, A., Kühnel, I., Prüfer, M., Zhang, C., Bodden, M., Rosigkeit, S., Waldmann, A., Tonn, T., Bockamp, E., Stein, S., & Wels, W. S. (2025). ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression. Molecular Therapy, 33(8), 3559-3575. https://doi.org/10.1016/j.ymthe.2025.04.033
Vancouver
Röder J, Alekseeva T, Kiefer A, Kühnel I, Prüfer M, Zhang C, et al. ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression. Molecular Therapy. 2025;33(8):3559-3575. doi:10.1016/j.ymthe.2025.04.033
BibTeX
@article{Rder2025,
author = {Röder, Jasmin and Alekseeva, Tijna and Kiefer, Anne and Kühnel, Ines and Prüfer, Maren and Zhang, Congcong and Bodden, Malena and Rosigkeit, Sebastian and Waldmann, Anja and Tonn, Torsten and Bockamp, Ernesto and Stein, Stefan and Wels, Winfried S},
title = {ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression},
journal = {Molecular Therapy},
year = {2025},
volume = {33},
number = {8},
pages = {3559--3575},
doi = {10.1016/j.ymthe.2025.04.033}
}
EUVIMED